Compositions for treating cell proliferation disorders

Details Compositions for treating cell proliferation disorders Compositions for treating cell proliferation disorders

2007-11-27

2007-11-27

Anderson, Rebecca (Department: 1626)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Heterocyclic carbon compounds containing a hetero ring...

C544S131000

Reexamination Certificate

active

11321419

ABSTRACT:
The invention relates to compounds and methods for treating cell proliferation disorders.

REFERENCES:
patent: 3868380 (1975-02-01), Molteni et al.
patent: 6844367 (2005-01-01), Zhu et al.
patent: 2005/0059713 (2005-03-01), Mjalli et al.
patent: 0 463 638 (1992-01-01), None
patent: WO 96/12473 (1996-05-01), None
patent: WO 99/01127 (1999-01-01), None
patent: WO 01/85726 (2001-11-01), None
patent: WO 03/059903 (2003-07-01), None
patent: WO 03/087057 (2003-10-01), None
patent: WO 03/093297 (2003-11-01), None
patent: WO 2004/056774 (2004-07-01), None
patent: WO 2005/013914 (2005-02-01), None
patent: WO 2005/032493 (2005-04-01), None
patent: WO 2007/026920 (2007-03-01), None
Cancer and Metastasis Reviews (1998), 17(1), 91-106.
Science (1999), vol. 286, 531-537.
A. Maureen Rouhi, Chemical & Engineering News, Feb. 24, 2003, pp. 32-35.
US Pharmacopia #23, national formulary #18, p. 1843-1844 (1995).
Huff, Journal of Medicinal Chemistry, vol. 34, No. 8, pp. 2305-2314, (1991).
Davidson et al., “Discovery and characterization of a substrate selective p38α inhibitor”,Biochemistry, 43:11658-11671 (2004).
Frame, M.C., “Src in cancer:deregulation and consequences for cell behaviour”,Biochem. Biophys. Acta, 1602:114-130 (2002).
Guo et al., “Tyrosine phosphorylation of the NR2B subunit of the NMDA receptor in the spinal cord during the development and maintenance of inflammatory hyperalgesia”,J. Neurosci., 22(14):6208-6217 (2002).
Hadjeri et al., “Antimitotic activity of 5-hydroxy-7-methoxy-2-phenyl-4-quinolones”.J. Med. Chem., 47:4964-4970 (2004).
Parang et al., “Recent advances in the discovery of Src kinase inhibitors”,Expert Opin. Ther. Patents, 15(9):1183-1207 (2005).
Paul et al., “Src deficiency or blockade of Src activity in mice provides cerebral protection following stroke”,Nat. Med., 7(2):222-227 (2001).
Yu et al., “Src, a molecular switch governing gain control of synaptic transmission mediated by N-methyl-D-asparate receptors”, Proc. Natl. Acad. Sci. USA, 96:7697-7704 (1999).

Affiliated with

Also associated with

Rating

Compositions for treating cell proliferation disorders does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Compositions for treating cell proliferation disorders, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compositions for treating cell proliferation disorders will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3864967